Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) Sees Significant Increase in Short Interest

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 615,400 shares, a growth of 26.7% from the December 15th total of 485,600 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 6,154.0 days.

Analysts Set New Price Targets

RCDTF has been the topic of a number of recent analyst reports. Barclays upgraded Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Stock Performance

Recordati Industria Chimica e Farmaceutica stock remained flat at $55.54 during mid-day trading on Friday. Recordati Industria Chimica e Farmaceutica has a 12 month low of $52.25 and a 12 month high of $52.25. The firm has a market cap of $11.46 billion, a PE ratio of 27.77 and a beta of 0.30. The firm’s fifty day simple moving average is $53.19 and its 200 day simple moving average is $52.47.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.